BTIG analysts continue to expect growth from Dexcom (Nasdaq:DXCM) after meeting with the company's senior investor relations (IR) officials.
LONDON--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced both the launch of Dexcom ONE+, a CGM ...
Dexcom has obtained European approval for the latest generation of its wearable diabetes sensor, the G7 continuous glucose monitor, for adults and children ages two and up. Designed to be 60% smaller ...
Dexcom will stop producing G6 CGM sensors July 1, 2026, urging patients to switch to the smaller, more accurate G7 model.
In the preceding three months, 12 analysts have released ratings for DexCom (NASDAQ:DXCM), presenting a wide array of ...
When Dan Heller received his first batch of Dexcom’s latest continuous glucose monitors in early 2023, he decided to run a small experiment: He wore the new biosensor and the previous generation at ...
(Reuters) -Dexcom said on Monday its over-the-counter continuous glucose monitor, Stelo, is now available for use in the United States at a price of up to $99. Stelo was cleared by the U.S. health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results